Varda Space Industries logo

Varda Space Industries

ActiveFounded 2021🇺🇸El Segundo, California
CEO

Will Bruey

Data verified as of Sep 1, 2026

Summary

Varda Space Industries manufactures materials in orbit and brings them back to Earth, a business no company had ever run commercially before it. Founded in 2021 by former SpaceX Dragon engineer Will Bruey and Founders Fund partner Delian Asparouhov, it builds the W-Series: free-flying spacecraft that process pharmaceuticals in microgravity and then return the product inside a capsule that reenters at over 18,000 mph and lands under parachute, usually at the Koonibba Test Range in South Australia. The commercial logic is that microgravity produces crystal structures and morphologies that gravity makes impossible on the ground, and Varda proved it on its first flight by growing and recovering the metastable Form III of ritonavir, an HIV antiviral. Six missions have flown since 2023, and five of the six capsules made it home; the fourth, W-4, spent nearly a year on orbit while Varda evaluated a propellant-feed problem before closing out the mission with a disposal burn in May 2026 rather than a recovery. W-5 returned in January 2026 as the first full mission on Varda's own vertically integrated satellite bus, carrying a U.S. Navy payload, and W-6 returned in May 2026 flying thermal-protection and autonomous-navigation experiments for NASA and defense customers under the AFRL's Prometheus program. That second business, selling the capsule as a cheap, high-cadence hypersonic reentry testbed, now runs alongside the pharmaceutical work, and in October 2025 Varda added a third line, agreeing with United Semiconductors to grow semiconductor crystals in microgravity for autonomous-systems, sensing, AI, and defense customers. In May 2026 United Therapeutics signed on to develop microgravity formulations for rare pulmonary disease, the first time a publicly traded pharmaceutical company has spent its own capital on commercial drug manufacturing in space, and Varda leased a former Mattel manufacturing plant in El Segundo in early 2026 to scale spacecraft production to match.

/ Recent News

View all →
  • View all news

    Browse the daily archive

Main Products

W-Series Spacecraft

Free-flying orbital production satellite with an integrated reentry capsule. It processes materials in microgravity independently of any space station, then returns the finished product to Earth under parachute.

Six missions launched since 2023 and five capsules recovered; W-4, the first in-house-built bus, was closed out with a disposal burn on May 10, 2026 after nearly a year evaluating a propellant-feed problem rather than being recovered. The spacecraft bus has been designed and built entirely in-house at El Segundo since W-4, and W-5's January 2026 return was the first complete mission lifecycle flown on Varda hardware end to end.

Missions Flown6 launched, 5 recovered (W-4 disposed of without recovery)
Reentry SpeedOver 18,000 mph, more than Mach 25
RecoveryParachute landing at Koonibba Test Range, South Australia
ManufacturingFull spacecraft built in-house in El Segundo since W-4
Reentry & Hypersonic Testbed

The W-Series capsule sold as a flight environment rather than a factory: a repeatable, low-cost way for defense and civil customers to test thermal protection materials, sensors, and guidance systems in real hypersonic reentry conditions.

W-6 launched in March 2026 and returned May 19, 2026 as a dedicated testbed flight funded through the Air Force Research Laboratory's Prometheus program, carrying NASA and defense payloads and validating next-generation thermal protection systems and autonomous navigation. W-5 carried a U.S. Navy payload on its January 2026 return.

ProgramAFRL Prometheus: $48M four-year IDIQ contract, running through early 2028
Testbed Flights in 20262 (W-5 in January, W-6 in May)
Regulatory BasisFAA reentry vehicle operator license, the first ever issued

What's Next

Fly the first United Therapeutics formulation missions

Begin processing small-molecule treatments for rare pulmonary disease aboard W-Series spacecraft under the collaboration announced in May 2026, using microgravity's effect on crystallization to chase formulations with better stability and bioavailability. CEO Will Bruey has said he expects the first United Therapeutics drug to fly in 2027; the partnership covers multiple low Earth orbit missions and is the first time a public pharmaceutical company has funded commercial space manufacturing from its own balance sheet.

2027

Raise reentry cadence toward routine operations

Increase the number of W-Series flights per year now that the spacecraft is built end to end in El Segundo, pursuing the company's stated goal of making reentry as common as launch. Under its expanded reentry agreement with Southern Launch, Varda is aiming to reach near-monthly capsule returns at the Koonibba Test Range by the end of 2028; it flew two recoveries in the first half of 2026 alone, with no seventh mission announced yet as of September 2026.

2028

Track Record

0 of 1 announced date hit · 1 missed

Resolve the W-4 capsule's return

Target 2026 · Resolved May 10, 2026

W-4's reentry attempt, waved off in December 2025 for propellant-feed system evaluation, was never rescheduled. Varda closed out the mission with a disposal burn on May 10, 2026 instead of a capsule recovery, ending W-4's flight without returning its payload. The company said the extra year of data from the standoff informed the W-5 and W-6 missions that followed.

Missed

Operations & Revenue

StatusOperational

Varda has flown six W-Series missions since 2023 and recovered five capsules, two of them in 2026 (W-5 in January and W-6 in May), both at Southern Launch's Koonibba Test Range in South Australia. The sixth vehicle, W-4, never came home: after nearly a year on orbit evaluating a propellant-feed problem, Varda closed out the mission with a disposal burn on May 10, 2026 instead of a recovery. The spacecraft bus is now built entirely in-house at El Segundo, where the company leased a third, 205,400-square-foot building (a former Mattel plant) in early 2026 to scale production, and an office is open in Huntsville near NASA Marshall. The company now runs three revenue lines: microgravity pharmaceutical processing, anchored by the United Therapeutics partnership signed in May 2026; a government hypersonic reentry testbed funded through AFRL's Prometheus program; and, since an October 2025 agreement with United Semiconductors, early-stage semiconductor crystal growth. No new W-Series launch or funding round has been announced since W-6's May 2026 reentry.

Revenue Streams

Pharmaceutical Processing in Microgravity

Contract manufacturing and formulation research for drug companies that want crystal structures and morphologies microgravity makes accessible, sold as processing slots aboard W-Series missions. The United Therapeutics collaboration covers multiple flights for rare pulmonary disease treatments.

Government Hypersonic Reentry Testbed

Selling the capsule itself as a low-cost, high-cadence flight environment for hypersonic and reentry experiments, funded through the Air Force Research Laboratory's Prometheus program and flown for NASA, the U.S. Navy, and defense customers.

Microgravity Research Services

General orbital processing and materials-science capacity for research customers who need a free-flying platform rather than a slot on a crewed space station.

Semiconductor Materials Manufacturing

A multi-flight joint development agreement with United Semiconductors, signed in October 2025, to grow bulk semiconductor and semimetal alloy crystals in microgravity aboard W-Series missions for autonomous-systems, sensing, AI, and defense hardware customers. Still early-stage; no flight-specific revenue has been disclosed.

Key Metrics

Employees

~250

Est. Annual Revenue

Not publicly disclosed (revenue from government reentry testbed contracts including a $48M AFRL Prometheus IDIQ, Navy payloads, pharmaceutical partnerships, and an early-stage semiconductor materials agreement)

Total Funding

$329M raised to date

Missions Launched

6 (W-1 through W-6), 5 capsules recovered (W-4 ended in a disposal burn, not a landing)

Reentry Velocity

Over 18,000 mph (Mach 25+)

Regulatory First

Holder of the FAA's first-ever reentry vehicle operator license (2025)

AFRL Prometheus Contract

$48M four-year IDIQ contract, running through early 2028

Valuation

~$500M (Series C, July 2025)

Timeline

2026W-5 returns on Varda's own vertically integrated bus

Launched November 28, 2025, W-5 lands at Koonibba on January 29, 2026 carrying a U.S. Navy payload. It is the first time Varda has flown a complete mission lifecycle, from orbital operations through reentry, on hardware it designed and built end to end.

2026Leases former Mattel plant in El Segundo to scale production

Varda signs a lease for a 205,400-square-foot former Mattel R&D building about a mile from its headquarters, giving it a third El Segundo site to build production and assembly capacity as it works toward roughly ten more spacecraft built by the end of 2027.

2026W-4 mission ends without recovery

After nearly a year on orbit while Varda evaluated the propellant-feed problem that forced it to wave off the reentry burn in December 2025, the company closes out the W-4 demonstration mission with a disposal burn on May 10, 2026 instead of a capsule recovery. Varda says the extra year of flight data informed the W-5 and W-6 missions that followed.

2026United Therapeutics signs the first commercial pharma partnership

In May 2026 Varda and United Therapeutics announce a collaboration to develop microgravity-enabled formulations of small-molecule treatments for rare pulmonary disease across multiple low Earth orbit missions. It is one of the first times a publicly traded pharmaceutical company has invested its own capital in commercial space-based drug manufacturing rather than relying on government-funded research.

2026W-6 flies as a hypersonic testbed for NASA and defense customers

Launched in March 2026 and recovered at Koonibba on May 19, 2026, W-6 is optimized for atmospheric flight physics rather than pharmaceutical processing. Funded through the Air Force Research Laboratory's Prometheus program, it carries NASA and defense payloads and validates next-generation thermal protection systems and autonomous navigation during hypersonic reentry.

2026Ex-Pfizer R&D chief Mikael Dolsten joins the board

Varda announces on August 3, 2026 that Mikael Dolsten, who spent 16 years as Chief Scientific Officer and President of Pfizer R&D overseeing more than 36 medicine and vaccine approvals, is joining its board of directors - a biopharma-credibility signal three months after United Therapeutics became the first pharma company to fund its own microgravity drug-development program on Varda's W-Series capsules.

2025W-2 and W-3 return to Australia

Varda shifts recovery operations to Southern Launch's Koonibba Test Range in South Australia. W-2 lands in February 2025 and W-3 follows in May 2025, giving the company two Earth returns in roughly two months and establishing a repeatable recovery cadence.

2025W-4 debuts the in-house bus and the FAA's first reentry operator license

W-4 launches in June 2025 on SpaceX's Transporter-14 carrying the first spacecraft bus Varda built itself rather than buying from Rocket Lab, and flies under the first reentry vehicle operator license the FAA has ever issued. Its return was deferred in December 2025 while the company evaluated the propellant feed system, and Varda has described W-4 as a demonstration mission with customer flights taking priority.

2025Varda and United Semiconductors agree to grow semiconductor crystals on orbit

In October 2025 Varda signs a multi-flight joint development agreement with United Semiconductors, which had already grown semiconductor crystals aboard the ISS National Lab, to produce bulk semiconductor and semimetal alloy crystals in microgravity aboard W-Series missions for autonomous-systems, sensing, AI, and defense hardware customers.

2024W-1 capsule returns to Earth

After months of regulatory delay in obtaining reentry approval, the W-1 capsule lands at the Utah Test and Training Range in February 2024 with its ritonavir sample intact. Varda later publishes results showing it recovered the metastable Form III of the drug, a structure difficult to produce on the ground.

2023W-1 launches with the first commercial orbital drug lab

Varda's first spacecraft launches in June 2023 on a Rocket Lab Photon bus and crystallizes ritonavir, an HIV antiviral, in microgravity, the first pharmaceutical ever manufactured commercially in orbit.

2021Founded to manufacture in orbit

Will Bruey, who worked on Dragon at SpaceX, and Delian Asparouhov, a partner at Founders Fund, found Varda in El Segundo with a single premise: microgravity is a manufacturing environment worth paying for, and the missing piece is a cheap way to bring the product home.

Funding

Cumulative disclosed raise · dated rounds

$200M$400M2022202320242025$328M raised
RoundDateAmountInvestorsSource
Seed2021$9MLux Capital, Founders Fund, Khosla Ventures
Series A2021$42MKhosla Ventures (lead), Lux Capital, Founders Fund, Caffeinated Capital
Series BApr 2024$90MCaffeinated Capital (lead), Founders Fund, Khosla Ventures, Lux Capital, Also Capital
Series CJul 2025$187M at a ~$500M valuationNatural Capital and Shrug Capital (co-leads), Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital, Also Capital

/ Related Companies

All Orbital Economy
SpaceX logo

SpaceX

Orbital Economy +2

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches reusable rockets and spacecraft. The company operates Falcon 9, Falcon Heavy, Dragon, Starlink, and the government-focused Starshield line while continuing to develop Starship for high-cadence heavy-lift missions to the Moon, Mars, and beyond. Starlink crossed 12 million customers across 160+ countries on June 4, 2026 and the constellation now exceeds 10,400 working satellites in orbit. Following the February 2026 xAI merger, SpaceX also operates the Memphis Colossus supercomputers as an AI hyperscaler, disclosing $14.1B of new Cloud Services Agreements signed in Q2 2026 alone (on top of the Anthropic, Google, and Reflection AI compute deals). SpaceX completed the largest IPO in history on June 12, 2026, debuting on Nasdaq under ticker SPCX at its fixed $135-per-share price for a roughly $1.77 trillion valuation and about $75B in proceeds, with Elon Musk retaining ~82% voting control; SPCX slid as low as $107.01 in late July before rebounding to close above its $135 IPO price on August 10, 2026 for the first time since mid-July. Starship returned to flight after the FAA closed the Flight 12 mishap investigation on July 13, 2026: on July 24, 2026 Flight 13 - the second flight of the Version 3 vehicle - deployed the program's first 20 operational Starlink V3 satellites and made the softest ship splashdown yet, and recovery crews towed the intact upper stage (Ship 40) through rough seas to Christmas Island, Australia by August 18, 2026 - the first Starship upper stage ever recovered intact after flight - before the semi-submersible vessel Forte departed Christmas Island on August 28, 2026 to carry it roughly 20,000 km back to Starbase, Texas. Days after its IPO, SpaceX agreed on June 16, 2026 to acquire AI coding startup Cursor's parent Anysphere for $60B in an all-stock deal - the largest acquisition of a venture-backed startup ever - and closed the deal on August 15, 2026, ahead of its late-August target, giving Cursor access to SpaceX's GPU fleet including the Colossus supercomputer. SpaceX posted its first earnings as a public company on August 4, 2026 (Q2 revenue of $7.8B, up 92% year over year, narrowing its net loss to $541M), and on August 11 Elon Musk told employees SpaceX's AI compute business would exceed all its other revenue by September 2026 and account for 99% of the company's value within five years, targeting 10 gigawatts of AI compute capacity - up from 1.4 GW at the end of Q2 - by the end of 2027. On August 25 SpaceX announced a $100 billion Starbase Louisiana spaceport in Vermilion Parish, with construction expected in 2027 and a first launch targeted as soon as 2029. A Falcon Heavy flew its 13th mission on August 30, 2026, launching NASA's Roman Space Telescope with both side boosters landing intact at Cape Canaveral, a day after NASA and SpaceX postponed the planned September 12 Crew-13 ISS launch when an oxidizer leak was found in Dragon's propulsion system during prelaunch processing. A mid-August 13F filing also disclosed Nvidia holds roughly $21B of SpaceX stock via its earlier xAI investment, as SpaceX committed on its August 4 earnings call to building its future AI compute exclusively on Nvidia's Vera Rubin architecture. SPCX shares climbed about 7% to close at $150.84 on September 3, 2026 after Oppenheimer raised its price target to $280 from $250 on growing confidence in the AI-compute business, with investors also looking ahead to the approaching Starship Flight 14 test.

Anduril Industries logo

Anduril Industries

Orbital Economy +1

Anduril Industries is an American defense technology company founded in 2017 by Oculus creator Palmer Luckey with Palantir veterans Brian Schimpf (CEO), Trae Stephens, Matt Grimm, and Joe Chen. Its core thesis is to build software-defined, mass-producible autonomous weapons around Lattice, an AI command-and-control platform that fuses sensor data and orchestrates fleets of unmanned systems. Its hardware now spans every domain: the Fury (FQ-44A) collaborative combat aircraft, Ghost and Bolt drones, Altius loitering munitions, Roadrunner reusable jet interceptors, Barracuda cruise missiles, Ghost Shark autonomous submarines, a new class of autonomous surface vessels built with South Korea's HD Hyundai, and the EagleEye mixed-reality soldier headset built with Meta. Anduril holds prime positions on several of the Pentagon's most-watched programs: the Air Force ordered its FQ-44A into production in June 2026 alongside General Atomics' FQ-42A, targeting at least 150 CCAs by the end of the decade, with a mission-autonomy software down-select still to come; it took over Microsoft's $22B IVAS soldier-headset program in 2025 (now SBMC) and is running a second prototype cycle after its Phase 2 hardware redesign, with an Army downselect and production decision potentially landing in fiscal 2028; it won a 10-year, $20B Army enterprise agreement for Lattice-based counter-drone command and control in March 2026; in August 2026 it demonstrated a Lattice-powered Battle Manager for the Guam Defense System at Exercise Valiant Shield, fusing Army, Air Force, Navy and Missile Defense Agency assets; and it leads an industry team prototyping Golden Dome space-based interceptors, which cleared the program's first design-review gate in August 2026. In August 2026 the Department of Homeland Security also awarded Anduril a Track 2 slot on a $1.5B, five-year counter-UAS IDIQ, though Anduril protested its exclusion from the Track 1 hardware award, with a GAO ruling due by November 20, 2026. International business is scaling too, led by Australia's A$1.7B Ghost Shark program, completed Altius-600M deliveries to Taiwan plus an August 2026 NT$26.9 billion (~$847 million) letter of offer and acceptance for 2,032 more Altius systems (1,554 Altius-700M loitering munitions and 478 Altius-600ISR, first deliveries in Q4 2026), a State Department-approved (not yet finalized) possible $1.98B Kuwait counter-drone Foreign Military Sale, and a July 2026 agreement for Poland's state defense group PGZ to build the surface-launched Barracuda-500M cruise missile locally - Anduril's first European production site - alongside an Embraer MoU to launch palletized Barracuda-500Ms from the C-390. Manufacturing is anchored by Arsenal-1, a $1B, 5-million-square-foot Ohio factory where the first Ohio-built Fury rolled off the line on July 27, 2026, months ahead of schedule, with Roadrunner, Barracuda, and a classified platform slated to join the line by year-end. Revenue roughly doubled in 2025 to $2.2B (2026 guidance points to roughly $4.3B), and the company raised a $5B Series H at a $61B valuation in May 2026, bringing total funding above $11B; reports since late July 2026 of a further round at roughly a $100B valuation remain unconfirmed and had not closed as of August 26, 2026. With around 7,000 employees, Anduril is the most richly valued private defense-tech company; CEO Brian Schimpf said in July 2026 the company is in no rush to IPO.

Astroscale logo

Astroscale

Orbital Economy +1

Astroscale is the only company in the world building a business purely around servicing what is already in orbit: removing debris, deorbiting dead satellites, extending the life of working ones, refueling them, and inspecting them. Founded in Tokyo in 2013 by Nobu Okada and listed on the Tokyo Stock Exchange Growth market since June 2024 under ticker 186A, it operates across Japan, the UK, the US, France, and Israel. Its ADRAS-J spacecraft made history in 2024 as the first vehicle ever to approach and photograph a large piece of orbital debris up close, a discarded Japanese rocket upper stage, and it completed operations and began its own deorbit in March 2026. JAXA has since contracted the follow-on ADRAS-J2 for roughly 12 billion yen to go back to that same rocket body and actually remove it with a robotic arm. Alongside that flagship line Astroscale is preparing ELSA-M, billed as the world's first commercial end-of-life deorbit service and now booked on Isar Aerospace's Spectrum rocket; LEXI, a geostationary life-extension servicer; the Astroscale U.S. Refueler, which is set to perform the first refueling of a United States Space Force asset; and ISSA-J1, a 2027 mission that will inspect two retired Japanese satellites in different orbits on a single flight. The company remains deeply loss-making: for the fiscal year ended April 30, 2026 it reported 5.94 billion yen of IFRS revenue against a 9.98 billion yen operating loss, with an order backlog of 37.94 billion yen. In June 2026 it closed a 30.6 billion yen strategic growth financing with Hulic and SKY Perfect JSAT to fund facility expansion and LEXI-P production.

Axiom Space logo

Axiom Space

Orbital Economy +1

Axiom Space, founded in Houston in 2016 by former NASA ISS program manager Michael Suffredini and entrepreneur Kam Ghaffarian, is the leading commercial human-spaceflight company, built around three lines of business: private astronaut missions to the ISS, the Axiom Station commercial space station, and next-generation spacesuits. It flew Ax-1, the first all-private crewed mission to the ISS, in April 2022, and has since flown four missions carrying 16 astronauts - most recently Ax-4 (June-July 2025), which returned India, Poland, and Hungary to human spaceflight; NASA has ordered a fifth mission (Ax-5, NET January 2027) whose crew remains unannounced as of August 2026. In 2020 NASA awarded Axiom a $140 million contract to attach the first commercial module to the ISS, and in September 2022 a $228.5 million task order (under a contract worth up to $1.26 billion) to build the Artemis moonwalking spacesuit, the AxEMU, covering four suits. NASA's early-2026 Artemis restructuring turned Artemis III into a non-landing rendezvous test flight and pushed the first crewed lunar landing to Artemis IV (targeted early 2028) - the mission the AxEMU suits are now built for; Axiom became NASA's sole suit developer after Collins Aerospace was descoped in 2024, and while a NASA OIG report in April 2026 warned the suit could still slip toward 2031, Axiom is running a roughly yearlong qualification-testing campaign toward a 2027 flight demonstration. The company hit severe financial turbulence in late 2024 - roughly 100 layoffs, voluntary 20% pay cuts, and late payments to contractors including SpaceX - followed by rapid CEO churn (Suffredini out August 2024, Ghaffarian interim, Tejpaul Bhatia April-October 2025, then NASA-veteran astrophysicist Jonathan Cirtain). In December 2024 it re-sequenced station assembly to launch a Payload Power Thermal Module first; that target has since slipped from NET 2027 to early 2028, with a free-flying station still expected to form as early as 2028. Finances have since stabilized: a $100M round at a ~$2B valuation (March 2025), $100M from Hungary's 4iG (December 2025), and an oversubscribed $525M+ round closed June 2026 with Qatar Investment Authority, Type One Ventures, and MUFG Bank. With ~700 employees, Axiom launched its first two orbital data center nodes in January 2026, plans a third node aboard the ISS with Spacebilt in 2027, is evaluating a role for that network in the Pentagon's proposed Golden Dome missile-defense architecture, and is competing for NASA's Commercial LEO Destinations Phase 2 award - whose original full-and-open competition structure NASA reaffirmed in June 2026 after briefly floating a government-owned core-module alternative in March - with a final RFP expected late August 2026 and selection targeted for spring 2027.

Blue Origin logo

Blue Origin

Orbital Economy +1

Blue Origin is a privately held aerospace company founded by Jeff Bezos that develops reusable launch vehicles, rocket engines, lunar landers, in-space mobility systems, and satellite communications infrastructure. Its current programs span the New Shepard suborbital system, the New Glenn heavy-lift rocket, the BE-4 engine family that also powers ULA's Vulcan, the Blue Moon lunar lander family, the Blue Ring spacecraft platform, and the TeraWave network. The FAA closed its NG-3 mishap investigation and lifted the New Glenn grounding on May 22, 2026 - pinning the BlueBird 7 deployment failure on a cryogenic leak that froze a hydraulic line - but six days later, on May 28, a New Glenn exploded during a hotfire at Cape Canaveral's LC-36, destroying the transporter-erector at Blue Origin's only New Glenn pad. CEO Dave Limp said the rocket will fly again before year-end via a hybrid horizontal-integration/crane-erect path that skips replacing the destroyed transporter-erector, with the propellant farm, a second flight-ready booster, and three upper stages intact; on July 24, 2026 NASA and Blue Origin agreed to conduct New Glenn second-stage (GS2) hot fire testing at Stennis Space Center's B-2 stand beginning this fall while LC-36 recovers, and NASA's Pegasus barge is due at Kennedy Space Center around August 10-12, 2026 to carry the completed GS2 to Stennis. The Blue Moon MK1 'Endurance' cargo lunar lander has completed thermal vacuum testing at NASA Johnson, but with New Glenn grounded its launch to the Moon has slipped from a fall-2026 target to early 2027. Separately, a February 2026 NASA Artemis architecture overhaul reassigned the crewed Blue Moon Mark 2 lander to compete with SpaceX's Starship for the program's first Moon landing (now targeted for Artemis IV, as soon as early 2028) following a 2027 crewed low-Earth-orbit docking test on the restructured Artemis III. In a landmark shift after 26 years of near-total self-funding (roughly $30B cumulative), Blue Origin raised about $10B at a $130B valuation in July 2026 - its first-ever outside round, led by Coatue (~$4B) with Jeff Bezos adding ~$2B - to bankroll Limp's target cadence of roughly 100 launches a year against an estimated ~$4.8B 2026 spend. Separately, Florida's governor announced on May 22, 2026 that Blue Origin will invest $600 million in an 830,000-square-foot upper-stage manufacturing expansion ("Project Horizon") at its Rocket Park campus in Merritt Island, adding about 500 jobs averaging over $98,000. The company broke ground on a new ~120,000-square-foot Cape Canaveral payload processing facility on August 31, 2026, and on September 1, 2026 NASA awarded it a $700M contract to build and deliver a Mars Telecommunications Orbiter - built on the Blue Ring platform - by December 31, 2028, extending Blue Origin's business beyond Earth-orbit launch and lunar landers into deep-space communications infrastructure. Bloomberg reported on September 3, 2026 that Blue Origin has hired at least 47 alumni of Amazon's Leo satellite venture over the past year, many now working on TeraWave, as it builds out its own broadband constellation team.

CASC logo

CASC

Orbital Economy +1

China Aerospace Science and Technology Corporation (CASC) is the state-owned prime contractor for China's space program and the world's most prolific launch organization by missions flown. Wholly owned by the central government through SASAC and led by chairman Chen Mingbo, it develops and operates the Long March (Changzheng) rocket family - which flew its 661st cumulative mission on August 4, 2026, delivering a 23rd batch of GuoWang broadband satellites - along with the Shenzhou crewed spacecraft, Tianzhou cargo vehicles, the Tiangong space station, BeiDou navigation and GuoWang broadband satellites, the Chang'e lunar and Tianwen planetary probes, and China's strategic missiles. After a national-record 73 launches in 2025, CASC is targeting over 100 launches in 2026 amid an industry-wide national push toward ~140, debuted the partially reusable Long March 12B in June 2026, and saw its Tianwen-2 probe reach the quasi-moon asteroid Kamo'oalewa on July 6, 2026. On July 10, 2026 it made China the second nation ever to recover an orbital rocket first stage, when the new single-stick, partially reusable Long March 10B flew its maiden mission from Hainan and captured its booster in a sea-based net - a landmark step toward closing the reusability gap with SpaceX, with a reflight of the recovered booster still targeted before the end of 2026. That momentum was interrupted on August 10, 2026, when a Long March 7A broke apart shortly after liftoff and lost its satellite payload - only the vehicle's second failure ever - triggering an engine investigation that put a question mark over the timing of Chang'e 7; CASC kept other Long March variants flying through the investigation, with a Long March 5B launching an eighth GuoWang satellite batch on August 13, 2026, and on August 19, 2026 rolled the Chang'e-7 probe and its Long March 5 (Y14) rocket out to the Wenchang pad ahead of a planned August 24, 2026 launch, but the mission was then postponed by Typhoon Narra and, per an August 23 China Manned Space Agency statement, cannot fly within the 2026 window at all - multiple outlets report a possible slip into 2027 - with no root cause or formal fleet clearance yet announced for the 7A investigation either. CASC is also advancing the triple-core Long March 10 toward a crewed Moon landing before 2030: the Long March 10A's own orbital debut is separately reported to carry a lunar navigation satellite ahead of the uncrewed Mengzhou 1 capsule test, still targeted around late 2026 but flagged as at risk of slipping into early 2027 - neither had flown as of September 8, 2026, and no Long March launch has been confirmed since the 665th mission on August 25. On August 28, 2026 the Shenzhou-23 crew completed its first spacewalk, repairing a Tiangong solar wing and installing debris shields.